Bristol Myers Squibb (CELG-RI) Other financing activities (2009 - 2022)

Bristol Myers Squibb (CELG-RI) has reported Other financing activities for 14 consecutive years, with $179.0 million the latest figure, recorded in Q4 2022.

• In Q4 2022, Other financing activities rose 6066.67% year-over-year to $179.0 million; the TTM figure through Dec 2022 stood at $984.0 million (up 53.51% YoY), while the FY2023 annual figure was $27.0 million, down 97.26% from the prior year.
• Other financing activities rose to $179.0 million in Q4 2022 per CELG-RI's latest filing, from $53.0 million in the prior quarter.
• Across five years, Other financing activities topped out at $419.0 million in Q2 2022 and bottomed at -$58.0 million in Q1 2018.
• Historically, Other financing activities has averaged $103.0 million across 5 years, with a median of $35.5 million in 2020.
• Annual changes were most pronounced in 2019 — Other financing activities plunged 1400.0% — and 2020, when it jumped 17200.0%.
• Bristol Myers Squibb's Other financing activities stood at $1.0 million in 2018, then slumped by 1400.0% to -$13.0 million in 2019, then soared by 2230.77% to $277.0 million in 2020, then tumbled by 101.08% to -$3.0 million in 2021, then jumped by 6066.67% to $179.0 million in 2022.
• Business Quant data shows CELG-RI's Other financing activities at $179.0 million in Q4 2022, $53.0 million in Q3 2022, and $419.0 million in Q2 2022.